Our R&D

Abbreviations: Second line+ (2L+), extensive-stage small cell lung cancer (ES-SCLC), Recurrent or metastatic (r/m), tissue factor (TF), hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), lupus nephritis (LN), atopic dermatitis (AD).

Notes: The trademarks and registered trademarks within are the property of their respective owners.* Greater China trial in preparation or under planning. Greater China = mainland China, Hong Kong, Macau and Taiwan, collectively. (1) Also launched in Hong Kong and Macau; (2) Commercially available in Hong Kong; (3) Greater China-only trial; (4) Also approved in Hong Kong and Taiwan; (5) Combination with carboplatin and KEYTRUDA +/- bevacizumab; (6) 1st line+ locally advanced or metastatic disease in solid tumors including colorectal cancer, pancreatic cancer, non-small cell lung cancer, and head and neck cancer; monotherapy and combination with KEYTRUDA and either carboplatin or cisplatin; (7) Global Phase 3 FORTITUDE-101 study and FORTITUDE-102 study enrollments completed; (8) Initiated enrollment of the proof-of-concept trials of LN in China in February 2023; (9) Zai Lab has exclusive license to develop and commercialize SUL-DUR in mainland China, Hong Kong, Taiwan, Macau, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan.

For more information about the above trials, please visit https://clinicaltrials.gov